Delving into the Latest Updates on MK-8504 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization-

Inactive Organization

Merck Sharp & Dohme Corp.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-retroviral therapy (ART) activity of monotherapy with MK-8504 (a tenofovir pro-drug), in ART-naïve Human Immunodeficiency Virus (HIV)-1 infected participants. The primary hypothesis is that MK-8504, at a dose that is sufficiently safe and well tolerated, has superior antiretroviral activity compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours post-dose.

Start Date08 Sep 2017

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

100 Clinical Results associated with MK-8504

Login to view more data

100 Translational Medicine associated with MK-8504

Login to view more data

100 Patents (Medical) associated with MK-8504

Login to view more data

1

Literatures (Medical) associated with MK-8504

01 Apr 2022·Acta Pharmaceutica Sinica B

Approved HIV reverse transcriptase inhibitors in the past decade

Review

Author: De Clercq, Erik ; Li, Guangdi ; Wang, Yali

HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice. Many RT inhibitors and their combination regimens have been approved in the past ten years, but a review on their drug discovery, pharmacology, and clinical efficacy is lacking. Here, we provide a comprehensive review of RT inhibitors (tenofovir alafenamide, rilpivirine, doravirine, dapivirine, azvudine and elsulfavirine) approved in the past decade, regarding their drug discovery, pharmacology, and clinical efficacy in randomized controlled trials. Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains.

100 Deals associated with MK-8504

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	United Kingdom	Merck Sharp & Dohme Corp.	08 Sep 2017
HIV Infections	Phase 1	Germany	Merck Sharp & Dohme Corp.	08 Sep 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03188523 (8504-002 \| MK-8504-002, CTgov)	Phase 1	HIV Infections	12	MK-8504 (MK-8504 100 mg (Panel A))	paypzfpaym(btnbtvrtai) = hpoetlgzny zcadqpunoh (nbinmvcuzq, jspiecfkys - tisuybtxca) View more	-	15 Jul 2019
				MK-8504 (MK-8504 240 mg (Panel B))	paypzfpaym(btnbtvrtai) = getuwozzjp zcadqpunoh (nbinmvcuzq, pxbfvdovbu - sxqedioxxz) View more